嚼服与吞服替格瑞洛对STEMI患者血小板抑制的影响
该随机临床试验纳入50例STEMI患者,比较嚼服180 mg负荷量替格瑞洛与常规口服等量药物在负荷后30分钟和1小时的血小板抑制作用;嚼服组在30分钟和1小时的P2Y12反应单位均显著低于常规组,30天主要不良心脑血管事件率低(4%),两组各1例。
要点
- 嚼服替格瑞洛180 mg负荷量可增强STEMI患者早期血小板抑制。
- 30分钟时嚼服组血小板反应性较常规组显著降低24%。
- 30天主要不良心脑血管事件率低(4%),两组各1例,需更大样本验证临床结局。
核心结论
- 在STEMI患者中嚼服替格瑞洛180 mg负荷量可行,且较常规口服等量负荷量能促进更好的早期血小板抑制。
- 嚼服组30分钟P2Y12反应单位显著低于常规组,1小时相对血小板聚集抑制率显著更高。
- 30天主要不良心脑血管事件率低(4%),两组各1例,研究结论需更大规模研究验证是否能转化为临床结局获益。
研究设计与样本
- 随机临床试验,2016年5月至10月在一家大型三级医疗中心开展,纳入30至87岁成人。
- 50例STEMI患者随机分为嚼服替格瑞洛180 mg负荷量组或常规口服等量负荷量组,采用意向性治疗分析。
- 使用VerifyNow(Accumentrics)在基线、负荷后30分钟、1小时和4小时评估P2Y12反应单位。
- 试验注册号clinicaltrials.gov NCT02725099。
主要发现
- 基线P2Y12反应单位均值(SD):嚼服组224(33)vs 常规组219(44)(95%CI,-16.77至27.73;P=.26)。
- 30分钟P2Y12反应单位:嚼服组168(78)vs 常规组230(69)(95%CI,-103.77至-19.75;P=.003)。
- 1小时P2Y12反应单位:嚼服组106(90)vs 常规组181(89)(95%CI,-125.15至-26.29;P=.005)。
- 4小时P2Y12反应单位:嚼服组43(41)vs 常规组51(61)(95%CI,-36.34至21.14;P=.30)。
- 嚼服组负荷后30分钟血小板反应性显著降低24%(95%CI,19.75至103.77;P=.001)。
关键数值与推荐
- 1小时相对血小板聚集抑制率:嚼服组51% vs 常规组10%(95%CI,13.69至67.67;P=.005)。
- 4小时相对血小板聚集抑制率:嚼服组81% vs 常规组76%(95%CI,-12.32至16.79;P=.24)。
- 30天主要不良心脑血管事件率4%,两组各1例(95%CI,0.06至16.93;P>.99)。
临床怎么用
- 对于STEMI患者,嚼服替格瑞洛180 mg负荷量可作为促进早期血小板抑制的可选给药方式。
- 该策略的临床结局获益尚未证实,需更大规模研究验证后再推广。
- 研究中两组30天主要不良心脑血管事件率均低,短期安全性初步可行。
局限性
- 样本量小(50例),研究结论需更大规模研究验证。
- 随访仅30天,主要不良心脑血管事件率低且两组各1例,无法评估临床结局差异。
- 研究时间为2016年5月至10月,单中心开展,外部推广性受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Dual anti-platelet therapy represents standard care for treating patients with ST-segment elevation myocardial infarction (STEMI). Ticagrelor is a direct-acting P2Y12 inhibitor and, unlike clopidogrel and prasugrel, does not require metabolic activation. OBJECTIVE: To evaluate whether chewing a loading dose (LD) of ticagrelor, 180 mg, vs traditional oral administration of an equal dose enhances platelet inhibition at 30 minutes and 1 hour after LD administration in patients with STEMI. DESIGN, SETTING, AND PARTICIPANTS: A randomized clinical trial was conducted in adults aged 30 to 87 years from May to October 2016 in a large tertiary care center. Analyses were intention-to-treat. INTERVENTIONS: Fifty patients with STEMI were randomized to either chewing an LD of ticagrelor, 180 mg, or standard oral administration of an equal dose. MAIN OUTCOMES AND MEASURES: P2Y12 reaction units were evaluated using VerifyNow (Accumentrics) at baseline, 30 minutes, 1 hour, and 4 hours after LD. RESULTS: Baseline characteristics were similar in both groups. The mean (SD) of P2Y12 reaction units in the chewing group compared with the standard group at baseline, 30 minutes, 1 hour, and 4 hours after ticagrelor LD were 224 (33) vs 219 (44) (95% CI, -16.77 to 27.73; P = .26), 168 (78) vs 230 (69) (95% CI, -103.77 to -19.75; P = .003), 106 (90) vs 181 (89) (95% CI, -125.15 to -26.29; P = .005), and 43 (41) vs 51 (61) (95% CI, -36.34 to 21.14; P = .30), respectively. Platelet reactivity in the chewing group was significantly reduced by 24% at 30 minutes after LD (95% CI, 19.75 to 103.77; P = .001). The relative inhibition of platelet aggregation in the chewing vs the standard group were 51% vs 10% (95% CI, 13.69 to 67.67; P = .005) at 1 hour and 81% vs 76% (95% CI, -12.32 to 16.79; P = .24) at 4 hours, respectively. Major adverse cardiac and cardiovascular event rate at 30 days was low (4%) and occurred in 1 patient in each group (95% CI, 0.06 to 16.93; P > .99). CONCLUSIONS AND RELEVANCE: Chewing an LD of ticagrelor, 180 mg, in patients with STEMI is feasible and facilitates better early platelet inhibition compared with a standard oral LD. Larger studies are warranted to see if our preliminary findings translate into clinical outcomes. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT02725099.
引用
- Asher E, Tal S, Mazin I, et al. Effect of Chewing vs Swallowing Ticagrelor on Platelet Inhibition in Patients With ST-Segment Elevation Myocardial Infarction: A Randomized Clinical Trial. JAMA Cardiol. 2017. PMID: 29071332. doi:10.1001/jamacardio.2017.3868
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。